Clinical Trials

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT06669572 2026-04-15

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

40 enrolled

Biliary Tract Neoplasms

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT05286437 2026-04-06

LaPemERLA

40 enrolled

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT07096609 2026-04-03

LONGIST

48 enrolled

Sarcoma

GIST

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT06110793 2026-03-30

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

49 enrolled

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

30 enrolled

Carcinoma, Renal Cell

NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

100 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT06859684 2026-03-09

HAIC-quad

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

18 enrolled

Endometrial Neoplasms

NCT07419932 2026-02-19

NeoLATC

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT07389629 2026-02-05

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Carcinoma, Renal Cell

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

72 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

15 enrolled

Advanced Gastric Adenocarcinoma

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

30 enrolled

Uterine Cervical Neoplasms

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

144 enrolled

Carcinoma, Hepatocellular

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Phase 1 Recruiting

12 enrolled

Triple Negative Breast Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT06230471 2025-12-09

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

60 enrolled

Biliary Tract Neoplasms Immunotherapy

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT05287464 2025-11-26

International Multicentric Study ARON-1

1,220 enrolled

Carcinoma, Renal Cell

NCT07149090 2025-11-20

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

61 enrolled

Stomach Neoplasms

NCT04887805 2025-11-19

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT04865887 2025-10-07

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

35 enrolled

Uterine Cervical Neoplasms

NCT05168163 2025-09-16

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

122 enrolled

Carcinoma, Hepatocellular

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

20 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT06740370 2025-08-14

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Phase NA Recruiting

32 enrolled

Carcinoma, Hepatocellular

NCT07070700 2025-08-12

CASTLE-ZS-02

56 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

120 enrolled

Breast Neoplasms

NCT06892925 2025-07-10

Spring

59 enrolled

Biliary Tract Tumors

NCT07047586 2025-07-03

LEAF-01

146 enrolled

Carcinoma, Hepatocellular

NCT06643208 2025-06-26

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

37 enrolled

Cholangiocarcinoma

NCT05774899 2025-06-17

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

32 enrolled

Carcinoma, Adenoid Cystic

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

92 enrolled

Stomach Neoplasms

NCT06318286 2025-05-25

PENINSULA

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

160 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06904196 2025-04-29

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

78 enrolled

Carcinoma, Hepatocellular

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Phase 3 Recruiting

480 enrolled

Cholangiocarcinoma

NCT05384015 2025-04-10

PEERS

46 enrolled

Thoracic

Lung Neoplasms

NCT05713994 2025-03-25

CCGLC-001

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

30 enrolled

Carcinoma, Hepatocellular

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

44 enrolled

HCC

NCT06208462 2025-03-03

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

33 enrolled

Cholangiocarcinoma

NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer